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Abstract
Not fully defined pathophysiologic mechanisms of inflammatory bowel disease (IBD) involve an
array of genetic, epigenetic, infectious, physiological and immunological factors. Nowadays, an
inadequate activation of the innate immune system to a luminal factor occurring in genetically
predisposed subjects is the most widely accepted today. Micro-autoimmune diseases, a group of
small, single-stranded, non-coding RNA molecules act as potent negative gene regulators.
Beyond cancer and various autoimmune diseases, their impact on IBD has recently been the focus
of research. Differential expression of various micro-RNAs has been documented in active and
inactive ulcerative colitis, while micro-RNA profile appears to differ between ileal and colonic
Crohn's disease. Except for tissue samples, attempts have been made to estimate similar
differences at patients' blood samples. Apart from offering new directions in related research,
these molecules arise as useful diagnostic tools and potential therapeutic targets. This review
focuses on micro-RNA alterations in IBD and their potential implication on immunologic
deregulation.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved..gr (M. Gazouli).
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Inflammatory bowel disease (IBD) ismainly represented by two
subtypes: ulcerative colitis (UC), which is a chronic and
recurrent inflammatory disorder of the colon and the rectum,
and Crohn's disease (CD), the other major autoimmune,
inflammatory disorder that affects more frequently the last
part of the ileum, the rectumand the sigmoid colon. These two
notions are standing in the two opposite ends of an imaginary
line, a fact that explains the inability to classify up to 10% of
IBD patients into either group and the diagnosis of indetermi-
nate colitis. The pathophysiology of it is not well defined yet,
but it seems that an array of genetic, epigenetic, infectious,
physiological and immunological factors plays an important
role in the expression and evolution of these diseases.1 What is
striking is that different pathophysiologic mechanisms are
involved and IBD has distinct gene and protein expression
signatures. Due to the complex etiology, the theory that IBD
and its gastrointestinal inflammation are the results of an
inadequate activation of the innate immune system to a
luminal factor (i.e. intestinal flora) occurring in genetically
predisposed subjects is the most widely accepted today. CD
and UC are associated with expression differences in genes,
involved in immune function, inflammation and tissue remo-
deling, including cytokines, growth factors, inflammatory
mediators, extracellular matrix proteins antimicrobial factors
and cell cycle regulators.2
2. Micro-RNAs
Micro-RNAs (Mi-RNAs) are a group of small (about 18–24
nucleotides in length), single-stranded, non-coding RNAFigure 1 miRNAs' biogmolecules that act as potent negative regulators in genes.
The biogenesis of miRNA remains still unknown but it is quite
clear that it is carried out in a multi-step process, from
longer pre-miRNAs in the nucleus, to mature mi-RNAs in the
cytoplasm.3 The maturation of miRNA occurs via a series of
steps and two main RNase III endonucleases (Drosha and
Dicer) are involved in this process. The inhibitory function of
mature miRNA is mediated by two main pathways: the
degradation of mRNA by binding of miRNA to the 3′ untrans-
lated region of mRNA, or direct repression of the transla-
tional process4 (Fig. 1). A number of biological processes are
regulated by miRNA, including cell survival, differentiation
and homeostasis; furthermore, specific miRNAs regulate the
differentiation of intestinal epithelial cells.5 While the
majority of studies are focused on the role of these
molecules in the development of cancer, their impact on
autoimmune diseases and especially IBD is much less studied.
It has been suggested that the critical function of these small
RNAs is to contribute to the establishment of immunological
homeostasis at mucosal sites. Recently, Biton et al.6 reports
on how intestinal epithelial miRNAs might regulate the
differentiation of goblet cells, the associated development
of antiparasitic T helper type 2 (TH2) immunity and the
expression of cytokines that generate crosstalk between gut
epithelial cells and the mucosal immune system.6 Addition-
ally, Tili et al.6 reported that specific miRNA, miR-155) is
induced by lipopolysaccharide stimulation to promote the
differentiation of native helper T cells into TH1 cells.
However, the role of miRNAs in the differentiation of
epithelial cells and regulation of mucosa immune system is
only just beginning to be explored. This review focuses on
whether and in which mi-RNAs, the expression is altered (up-
or down-regulation) in immune function, and theirenesis and function.
522 P. Archanioti et al.implication in IBD. To better comprehend the involvement of
mi-RNAs in the immunological derangement of these
diseases, an attempt will be made to clarify their role in
the development and function of immune cells.3. Mi-RNAs and immune response
Given the results of multiple studies and experiments in the
understanding of the immune response, it's not surprising
that mi-RNAs build another step in the development and
physiology of the immune system. There are several reports,
where genetic ablations in the algorithm of mi-RNA maturing
and incorporation in the human genome, play an important
role in the deregulation of the function of immune system.
For example, a deletion of Dicer (ribonuclease III enzyme) in
the mi-RNA processing machine in immature double negative
thymocytes leads to a reduction of the total number of
thymocytes. Very few peripheral T cells are detectable when
Dicer is deleted at the double-positive stage of thymocyte
differentiation, and the peripheral CD4+ T cell population is
reduced.7 The expression of miR-150 increases during both
B-cell maturation in the bone marrow and T-cell maturation
in the thymus, but decreases rapidly when naïve T-cells
differentiate into Th1 or Th2 cells. Similarly when Dicer is
deleted in the B-cell lineage from the earliest stage of B-cell
development, the pro-B to pre-B transition is almost
completely blocked. This is, at least in part, due to the
apoptosis of Dicer-deficient pro-B cells.8 According to
another recent study9 the miR-150 regulates the transition
from the pro- to pre-B-cell stage, and over-expression of this
miRNA prevents B-cell development.10 Interestingly, miR-
155 is required for T-cell differentiation and, also, the
deletion of miR-155 results in a diminished germinal center
response and impaired B-cell memory formation.11 Addi-
tionally, the same study shows that miR-146 is also important
for the toll-receptor (TLR) signaling in the innate immune
system. In human monocytes, expression of miR-146a and
miR-146b is induced by exposure to TLR ligands, lipopoly-
saccharide (LPS,) peptidoglycan, and flagellin.12 Micro-RNA,
miR-146a reduces expression of 2 components of the TLR
signaling cascade: i. TNF-receptor-associated-factor (TRAF)-
6 and ii. IL-1-receptor-associated kinase (IRAK)-1. Thus,
increased miR-146 expression leads to a negative feedback
that attenuates the TLR response. While miR-155 and miR-
146 expression is increased in macrophages in LPS stimula-
tion, miR-125b expression is decreased. MiR-125b targets
TNF-α, and thus, decreased expression of miR-125b leads to
an increased inflammatory response due to an elevated
expression of TNF-α.64. Mi-RNAs in UC
The growing understanding of the importance of mi-RNAs in
innate and adaptive immunity has been followed by several
studies identifying the differential expression of mi-RNAs in
immune-mediated disorders such as psoriasis, atopic ecze-
ma, rheumatoid arthritis (RA), asthma, and systemic lupus
erythematosus (SLE).9 As the specific differential expression
of mi-RNAs has been confirmed for many immune-mediated
disorders, UC and CD may uniquely demonstrate somedifferentially expressed mi-RNAs. Recently, mi-RNA micro-
array analysis and reverse transcription polymerase chain
reaction (RT-PCR) validation of the active UC patient group
compared to the inactive group revealed distinct mi-RNA
expression patterns in patients with active versus inactive
UC.9 Of the 3 mi-RNAs that were decreased in active UC,
miR-192 was unchanged in inactive UC compared to healthy
patients, while miR-275 and miR-422b were increased in
inactive UC. Of the 8 mi-RNAs with increased expression in
active UC, 4 had similar expression levels in inactive UC (miR-
23a, miR-16, miR-24, and miR-29a), while the expression of
miR-21, miR-126, miR-195, and let-7f was more consistent
with the levels seen in control individuals. This difference
suggests that some mi-RNAs may be involved in the chronic,
dysregulated immune response, while other miRNAs are
involved only in acute inflammation.9 The alteration of mi-
RNA expression, though, was not confined to inflamed, but
pre-existed in non-inflamed mucosa.13 It was identified that
14 and 23 mi-RNAs were respectively altered in UC and CD, of
which 8 were similarly dysregulated both in non-inflamed UC
and CD biopsies.13 Wu et al.14 have also confirmed such an
observation; mir-26a and mir-29a are up regulated in
quiescent UC mucosa.14 Altogether, these results support
the notion that dysregulation of mi-RNA expression pre-
exists in the quiescent colonic mucosa of UC and CD patients
and may play a key role in the sensitization of the quiescent
mucosa to environmental factors and/or IBD inducers.13 The
study by Wu et al.14 concerning the altered expression of mi-
RNAs in UC tissues shows that 3 mi-RNAs (miR-192, miR-375
and miR-422b) were significantly decreased in active UC
tissues whereas 8 mi-RNAs (miR-16, miR-21, miR-23a, miR-
24, miR-29a, miR-126, miR-195, and let-7f) were significant-
ly increased in active UC tissues, as compared to healthy
control tissues.14 After the mi-RNA microarray analysis and
qRT-PCR the miRNAs: miR-192 and miR-21 were identified as
the most highly expressed of the active UC-associated
miRNAs in human colon tissues. Furthermore the expression
of miR-192 was also found to be predominately expressed in
epithelial cells in the normal colon (non-inflamed colon). The
same study demonstrates an inverse correlation between the
expression of miR-192 and MIP-2a, an epithelial cell-
expressed cytokine produced by colonic epithelial cells and
macrophages.14 In addition, in the same colonic epithelial
cells, TNF-a-induced MIP-2a expression was also influenced
by miR-192, and previous studies have shown that miR-192
was induced by transforming growth factor (TGF)-β.14,15 Its
regulation by TGF-β and TNF-α and its regulation of collagen
and chemokine expression indicate that miR-192 may play a
key role in inflammation and fibrosis. Concerning the other
active-UC associated mi-RNAs, it was indicated that only
three could have a potential role in inflammation: miR-21,
miR-16, and let-7f.14,15
Another study brings into light further information
concerning the potential role of another miRNA with altered
expression in UC.16 Differentially expressed miRNAs were
observed in patients with active UC (pinched biopsies from
the sigmoid colon). Using miRNA microarray and real time
PCR, it was demonstrated that miR-21 and miR-155 were up
regulated in the inflamed colonic mucosa.16 The miR-21 had
already been reported in Wu et al.'s14 study, but this was the
first report for the possible role of miR-155. Recently, miR-
155 was identified and characterized as a component of the
Table 1 miRNAs that demonstrate differential expression in ulcerative colitis (UC) and Crohn disease (CD).
Disease Tissue Associated miRNAs Reference
Active UC (compared to
healthy controls)
Sigmoid colon
biopsies
Increased expression: miR-16, miR-21, miR-23a, miR-24,
miR-29a, miR-126, miR-195, let-7f
12
Decreased expression: miR-192, miR-375, miR-422b
Chronically active CD (compared to
healthy controls)
Sigmoid colon
biopsies
Increased expression: miR-23b, miR-106a, miR-191 13
Decreased expression: miR-16b and miR-629
Chronically active CD (compared to
healthy controls)
Terminal ileal
biopsies
Increased expression: miR-16, miR-21, miR-223, miR-594 13
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matory mediators. In the immune system, miR-155 expres-
sion is increased in activated B and T cells, and in dendritic
cells (DC).17–20 Micro-RNA miR-155 plays an important role in
the differentiation of B and T cells,21 and contributes to the
development of regulatory T cells. In mature human DC, miR-
155 is part of a negative feedback loop that down-modulates
inflammatory cytokines production in response to microbial
stimuli.20 Thus, miR-155 is a component of the innate
immune response to a broad range of inflammatory
mediators, both viral and bacterial.
5. Mi-RNAs in CD
Another study by Wu et al. has shown that mi-RNA expression
is not only altered in biopsies of patients with active CD, but
there is also an intestinal region-specific miRNA expression,
which is altered in ileal CD (Crohn's ileitis) and colonic CD
(Crohn's colitis).15 More specifically, in Crohn's ileitis, the
initial mi-RNA microarray profiling and, later, the validation
by mature mi-RNA qPCR confirms that 3 micro-RNAs are
increased in active CD tissues; miR-23b, miR-106, and miR-
191.15 Additionally, it is important that these mi-RNAs were
not previously identified as UC-associated miRNAs and the
lack of their altered expression in active UC was confirmed.
Furthermore, the initial microarray profiling and validation
by miRNA qPCR has identified two other miRNAs to be under-
expressed: miR-19b, and miR-629. The latter had neither
been previously identified in UC.15 To confirm the initial
hypothesis of miRNAs differential expression in Crohn's
ileitis, Wu et al.15 conducted a similar assessment comparing
the miRNA expression in terminal ileal biopsies from patients
with chronically active terminal ileal CD. Results demon-
strate four miRNAs to be significantly over-expressed; miR-
16, miR-21, miR-223, miR-594.15 It can be suggested that
IBD-associated mi-RNAs and intestinal tissue region specific
mi-RNAs are involved in the maintenance of intestinalTable 2 miRNAs could distinguish active CD from active UC.
Disease Tissue Associated miRNAs
Active CD (compared to
healthy controls)
Peripheral
blood
Increased expression: m
miRplus-E1271
Decreased expression:
Active UC (compared to
healthy controls)
Peripheral
blood
Increased expression: m
miR-340, miRplus-E1271
miR-3180-3p, miRplus-E
Decreased expression:homeostasis and in differences in the pathogenesis of IBD
subtypes. In particular, it is noteworthy that there was very
little overlap between the expression levels of specific
miRNAs in active UC, Crohn's colitis, and Crohn's ileitis. It
has been demonstrated in this study that none of the active
UC-related miRNAs, including miRs-16, -21, -23a, -24,
-29b, -126, -192, -195, -375, -422b, and let-7f, is altered in
Crohn's colitis tissues. Similarly, none of the Crohn's colitis-
associated miRNAs has been previously found to be altered in
UC tissues.15 Among the miRNAs altered in Crohn's ileitis,
only miR-16 and miR-21 have been identified to be altered in
UC, but not in Crohn's colitis.15 Table 1 is a summary of the
several miRNAs involved and their differential expression in
UC and CD.
6. Mi-RNAs in peripheral blood of IBD patients
Differential mi-RNA expression in UC and CD has been
demonstrated in experiments that included mostly human
tissues collected by colonoscopic biopsies, which automati-
cally rendermi-RNA expression profile analysis thatmakes this
an invasive method. Recent research has been expanded in
detection of differential miRNA expression in blood samples.9
According to the derived data, CD and UC differ not only in
their tissue miRNA but also in their peripheral blood miRNA
profiles.9 More specifically, mi-RNA microarray analysis was
performed in patients with active and inactive CD and UC.9
Four miRNAs; miR-199a5p, miR-362-3p, miR-532-3p, and
miRplus-E1271 were increased and one mi-RNA (miRplus-
F1065) was decreased in the peripheral blood of patients with
active CD, but not in the blood of patients with inactive CD,
compared to healthy controls.9 Both patients with active and
inactive CD had increased expression of miR-340 and
decreased expression of miR-149.9 Similarly, in active UC
patients' blood, 9 miRNAs were found to have an increased
expression.9 Three othermiRNAs (miR-103-2,miR-262-3p, and
miR-532-3p) were increased in the blood of both active andReference
iR-199a-5p, miR-362-3p, miR-340, miR-532-3p, 20
miR-149, miRplus-F1065
iR-28-5p, miR-151-5p, miR-199a-5p,
, miR-103-2, miR-362-3p, miR-532-3p,
1035, miRplus-F1159
20
miR-505
524 P. Archanioti et al.inactive UC patients.12 Additionally, 11 miRNAs could distin-
guish active CD from active UC (Table 2).12 But in the same
time, in the study of Taganov et al.12 the miRNA expression
among the patients with active CD didn't differ significantly
between Crohn's ileitis and Crohn's colitis sub-groups. Thus,
differences in peripheral bloodmiRNAexpression didn't appear
to be related to the distribution of disease activity. It has to be
mentioned that in this study no miRNAs common between the
tissue biopsies and the blood samples in patients with Crohn's
colitis, Crohn's ileitis and active UC were found to be
differentially expressed. Since miRNAs in peripheral blood
likely reflect expression in circulating white blood cells, this
miRNA expression would not be expected to be the same as
that seen in ileal and colonic epithelial cells. In contrast,
differential whole blood miRNA expression is expected
between CD and UC, since the two diseases differ in their
associated T- and B-cell subtypes.7. Conclusion
All these studies and the growing interest of scientific
community, concerning the role of micro-RNAs in the
presentation and evolution of the diseases associated with
disorders in the immunity system, certify their fundamental
role. These molecules may be influenced by inflammatory
factors, before the presence of the phenotypic and clinical
expression of an autoimmune, or/and inflammatory bowel
syndrome. They may likely act as genetic signatures for these
entities, as they vary according to the type and the
evolutionary stage of IBD. Contemporary studies have
demonstrated not only the existence of alterations in
numerous mi-RNAs, but also confirmed the sensitivity and
the specificity of certain miRNAs expressions for each one of
the different subtypes in IBDs. Apart from offering new
directions in related research, data extracted from similar
future studies may expand the role of these molecules as
useful, less invasive diagnostic tools and potential therapeu-
tic targets.References
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